DNA Software company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Founded Year



Grant | Alive

Total Raised


Last Raised

$2.5M | 13 yrs ago

About DNA Software

DNA Software, Inc. (DNAS) was founded in December 2000, and is aiming to model the interactions of nucleic acids in genomic assays in-silico. DNA Software's core technology is the Oligonucleotide Modeling Platform (OMP).

DNA Software Headquarter Location

204 East Washington Street

Ann Arbor, Michigan, 48104,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing DNA Software

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

DNA Software is included in 1 Expert Collection, including Omics.



1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

DNA Software Patents

DNA Software has filed 2 patents.

patents chart

Application Date

Grant Date


Related Topics




Remote desktop, Computer memory, Computer network security, Virtual private networks, Network protocols


Application Date


Grant Date



Related Topics

Remote desktop, Computer memory, Computer network security, Virtual private networks, Network protocols



Latest DNA Software News

Fluidigm Announces Agreement with DNA Software to Offer Secondary CNV Analysis for Biomark HD

Oct 4, 2018

| Source: Fluidigm Corporation SOUTH SAN FRANCISCO, Calif., Oct. 04, 2018 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM ) today announced that it has entered into a non-exclusive distribution agreement with DNA Software, Inc. to provide CopyCount-CNV™ software for use with the Fluidigm Biomark™ HD system. Copy number variation (CNV) plays an important role in a number of complex human diseases and in drug metabolism. It occurs when the number of copies of a given gene or genomic region varies between individuals within a population. Biomark HD utilizes microfluidics technology to efficiently detect CNVs, with significant cost and time savings over traditional plate‑based methods. Ideal for analysis of tens to hundreds of samples, Biomark HD is a high-performance automated qPCR platform used by researchers around the globe to advance our understanding of health and disease through gene expression, genotyping, CNV analysis and digital PCR. CopyCount-CNV software from DNA Software complements the Biomark HD workflow by providing researchers with a powerful software solution to measure CNVs with high accuracy. It uniquely determines the absolute copy number of each marker from raw fluorescence qPCR data and computes the ratio of those copy numbers to reveal the CNV. Providing statistical confidence metrics not available in other CNV analysis software, CopyCount-CNV further empowers researchers to maximize performance within their own assay pipelines. “The combination of the easy-to-use CopyCount-CNV software and the proven, high-performance Biomark HD automated qPCR system from Fluidigm has the potential to result in more accurate CNV determination in both translational and clinical research,” said Dr. John SantaLucia, co-founder, President and CEO of DNA Software. “With DNA Software, we share a goal of providing high‑performing, cost‑effective workflows to meet the growing demands of molecular laboratories,” said Chris Linthwaite, President and CEO of Fluidigm. “With this agreement, we are excited to offer an expanded Biomark HD workflow to fuel new breakthroughs that can improve the future of health care.” About DNA Software, Inc.  DNA Software, Inc. provides software to the life sciences to improve the design and analysis of molecular assays by reducing errors, time to market and related R&D costs. About Fluidigm Corporation  Fluidigm (NASDAQ: FLDM ) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single‑cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures. We use our website ( www.fluidigm.com ), corporate Twitter account ( @fluidigm ), Facebook page ( https://www.facebook.com/fluidigm ), and LinkedIn page ( https://www.linkedin.com/company/fluidigm-corporation ) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts. Fluidigm, the Fluidigm logo, and Biomark are trademarks or registered trademarks of Fluidigm Corporation. All other trademarks are the sole property of their respective owners. Forward-Looking Statement for Fluidigm   This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding potential uses and benefits of Biomark HD and CopyCount-CNV software. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to uncertainties in contractual relationships; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; the uncertain regulatory environment; potential product performance and quality issues; intellectual property risks; competition; and interruptions or delays in the supply of components or materials for, or manufacturing of, Fluidigm products. Information on these and additional risks and uncertainties and other information affecting Fluidigm business and operating results are contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2017, and in its other filings with the Securities and Exchange Commission, including Fluidigm’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2018. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law. Contacts:

DNA Software Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

DNA Software Rank

  • When was DNA Software founded?

    DNA Software was founded in 2000.

  • Where is DNA Software's headquarters?

    DNA Software's headquarters is located at 204 East Washington Street, Ann Arbor.

  • What is DNA Software's latest funding round?

    DNA Software's latest funding round is Grant.

  • How much did DNA Software raise?

    DNA Software raised a total of $2.5M.

  • Who are DNA Software's competitors?

    Competitors of DNA Software include NuGEN Technologies, Thermal Gradient, Genvault Corporation, Proteopure, EpigenDX and 8 more.

You May Also Like

Thermal Gradient Logo
Thermal Gradient

Thermal Gradient is a developer of devices and systems for rapid, easy-to-use molecular diagnostic systems. The company's proprietary fast thermal cycling and nucleic acid extraction and purification technologies enable extremely fast and easy to use systems to be brought to point-of-care whether for field use in low resource settings or distributed diagnostics in the developed world. The same advantages open up significant licensing and cartridge supply opportunities in bio-defense and other molecular biological applications.

Dna Labeling

Dna Labeling commercializes DNA labeling technology from the University of Toronto.


SeiraD is engaged in research and development creating instrumentation for scientific problems. Their current focus is the DNA sequencing instrument.

EpigenDX Logo

EpigenDx is a genomic and epigenomic research company engaged in disease biomarker discovery and molecular diagnosis. The company aims to provide products related to DNA methylation analysis research. Currently available products include DNA methylation controls and validated DNA methylation assays for human, mouse, and rat. The company also aims to provide products and laboratory services for scientific researchers from academic, government and industrial communities. The company's commitment to quality comes from the company's desire and dedication to provide products and services to the company's customers. As a Biotage AB Certified Laboratory Service provider, EpigenDx has knowledge and expertise in Pyrosequencing and its many applications. CpG methylation and allele quantification analysis are conducted using Biotage's PSQ MD system, while short-read sequence analysis is carried out using Biotage's PSQ ID system.

Promega Logo

Promega is engaged in applying biochemistry and molecular biology to the development of high-value biological reagents and systems for the life sciences industry.

EMD Biosciences

EMD Biosciences, Novagen Brand, manufactures and sells molecular biology tools--including gene splicers, protein purifiers, and more--that boost important research and development involving DNA, genes, proteins and other building blocks of life.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.